Choksi Laboratories Ltd Valuation Shifts to Very Attractive Amid Mixed Market Performance

Valuation Metrics Signal Improved Price Attractiveness

Choksi Laboratories currently trades at a P/E ratio of 66.3, which, while high in absolute terms, is considered very attractive relative to its historical valuation and peer comparisons within the healthcare services industry. The company’s price-to-book value stands at 4.93, a figure that has also improved from previous levels, signalling a more favourable entry point for value-conscious investors.

Other valuation multiples include an EV to EBIT of 30.6 and an EV to EBITDA of 12.53, which are moderate when benchmarked against peers such as KMC Speciality and Gujarat Kidney Institute, which exhibit EV to EBIT multiples of 28.32 and 56.09 respectively. The EV to Capital Employed ratio of 2.79 and EV to Sales of 3.35 further reinforce the notion that Choksi Laboratories is trading at a relatively reasonable valuation given its operational scale and capital structure.

Peer Comparison Highlights Relative Attractiveness

When compared to its peer group, Choksi Laboratories stands out for its very attractive valuation grade. For instance, KMC Speciality and Gujarat Kidney Institute are rated as very expensive with P/E ratios of 50.25 and 97.17 respectively, while Suraksha Diagnostics and Hemant Surgical fall into the expensive or fair categories. In contrast, Choksi’s PEG ratio of 2.49, though higher than some peers, reflects a balanced growth-to-valuation trade-off, especially when considering its return metrics.

Peers such as Asarfi Hospital and Hannah Joseph, rated very attractive and attractive respectively, trade at significantly lower P/E ratios of 19.56 and 20.91, but their growth prospects and market capitalisation differ markedly from Choksi Laboratories, which remains a micro-cap with a market cap grade reflecting its smaller scale.

Financial Performance and Returns Contextualise Valuation

Choksi Laboratories’ latest financial returns provide a mixed but generally positive backdrop to its valuation. The company’s return on capital employed (ROCE) stands at 8.95%, while return on equity (ROE) is 7.43%. These figures, though modest, indicate operational efficiency and moderate profitability in a competitive healthcare services environment.

Examining stock returns relative to the Sensex reveals a strong outperformance over longer horizons. The stock has delivered a 5-year return of 752.71%, vastly outpacing the Sensex’s 22.37% over the same period. Even over three years, Choksi Laboratories has returned 204.79%, compared to the Sensex’s 9.24%. However, more recent performance shows some volatility, with a 1-week decline of 8.94% against the Sensex’s 2.27% drop and a 1-year return of -1.82% versus the Sensex’s -11.20%, suggesting some short-term market pressures.

Price Movement and Trading Range

The stock closed at ₹181.20 on 5 Oct 2026, down 1.47% from the previous close of ₹183.90. The day’s trading range was between ₹174.75 and ₹182.00, while the 52-week range spans from ₹81.85 to ₹216.95. This wide range reflects significant volatility but also highlights the stock’s capacity for substantial appreciation, as evidenced by its multi-year returns.

Despite the recent dip, the current price remains well above the 52-week low, indicating resilience. The valuation shift to very attractive suggests that the market may be pricing in a more favourable risk-reward profile, potentially signalling a buying opportunity for investors willing to tolerate micro-cap volatility.

Mojo Score and Grade Update

Choksi Laboratories’ Mojo Score currently stands at 47.0, with a Mojo Grade downgraded from Hold to Sell as of 1 Oct 2026. This downgrade reflects concerns around certain operational or market risks that have emerged, despite the improved valuation metrics. The micro-cap status of the company also implies higher risk and lower liquidity, factors that investors should weigh carefully.

While the valuation parameters have improved, the overall sentiment as captured by the Mojo Grade suggests caution. Investors should consider the balance between attractive pricing and the underlying fundamentals that have led to the recent downgrade.

Investment Considerations and Outlook

Investors analysing Choksi Laboratories should weigh the improved valuation metrics against the company’s operational performance and market risks. The very attractive P/E and P/BV ratios relative to peers and historical levels suggest that the stock is priced favourably, potentially offering upside if the company can sustain or improve its returns on capital.

However, the downgrade to a Sell rating by MarketsMOJO’s grading system signals caution. The micro-cap nature of the stock entails higher volatility and liquidity risk, which may not suit all investors. Additionally, the PEG ratio of 2.49 indicates that growth expectations are priced in to some extent, and any slowdown could impact valuations.

Long-term investors may find the stock’s historical outperformance compelling, but short-term traders should be mindful of recent price declines and the broader market context. The healthcare services sector remains competitive, and Choksi Laboratories will need to demonstrate consistent operational improvements to justify its valuation premium.

Summary

Choksi Laboratories Ltd’s valuation has shifted to a very attractive zone, with key multiples such as P/E and P/BV improving relative to peers and historical averages. Despite a recent downgrade in its Mojo Grade to Sell, the stock’s long-term returns and relative valuation present a nuanced picture for investors. While the micro-cap status and recent price volatility warrant caution, the current price levels may offer a favourable entry point for those with a higher risk appetite and a long-term investment horizon.

Careful monitoring of operational metrics and sector dynamics will be essential to assess whether the valuation attractiveness translates into sustainable investment gains.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →